key: cord-0971011-avf1n9uj authors: Cao, L.; Zhao, S.; Lou, J.; Zheng, H.; Mok, C. K. P.; Chan, R. W.; Chong, K. C.; Chen, Z.; Chan, P. K.; Zee, B. C.-Y.; Wang, M. H. title: Genetic mismatch explains sizable variation of COVID-19 vaccine efficacy in clinical trials date: 2021-04-22 journal: nan DOI: 10.1101/2021.04.22.21254079 sha: 7e9c74afbc6efced5ca240c073a840bde98b0622 doc_id: 971011 cord_uid: avf1n9uj Pulling vaccine efficacy and effectiveness (VE) outcomes from 17 reports of 9 different vaccine products and through sequence analysis, we found that genetic mismatch explained sizable variations in VE. The findings suggested the potential need of timely optimizing vaccine antigens as new dominant viral strains emerge. The novel coronavirus disease 2019 (COVID-19) has caused devastating consequences to global health. 27 Vaccines against the pathogen, SARS-CoV-2, bear the hope of reducing the COVID-19 associated severe 28 diseases, mortality and mitigating the pandemic scale. To date, over 90 vaccine candidates have been tested in 29 phase 1/2/3 trials, and 13 products have been approved in at least one country [1] . Vaccine efficacy 30 summarizes the relative proportion of protection against a disease outcome in the vaccinated group versus the 31 placebo group in clinical trials, while vaccine effectiveness measures this quantity in a real-world scenario. 32 The published clinical trial data for COVID-19 vaccines exhibited a large variation in efficacy ranging from 33 location of the clinical trials or the observational study were downloaded. After removing duplicated strains, a 59 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Turkey, the United Arab Emirates, the United Kingdom, and the United States of America. The collection 62 date of the sequences ranged from January 1, 2020 to April 1, 2021. Multiple sequence alignment was 63 performed using MAFFT (version 7). The 'Wuhan-Hu-1' genome (GenBank 'NC_045512.2', GISAID 64 'EPI_ISL_402125') was considered as the reference sequence. All sequence data used in the analysis were 65 listed in the Supplementary Acknowledgement Table. 66 Table S1 .2). The statistical relationship between genetic mismatch and VEs was evaluated following the 74 general framework proposed in our previous study for influenza vaccine [4] . As the main target of the 75 COVID-19 vaccine is S protein and restricted by sample size, we adopted a simpler version of the model with 76 only one variable, genetic distance (G), as the predictor, and VE being the dependent variable, and the model 77 Figure 1c) . 94 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The results show that the RBD region plays a dominant role in affecting the VEs. We estimated that the 96 average VE reduction stemming from per amino acid substitution in the RBD is 22.6% [95% CI: 15.7 -97 29.6%], see Figure 1b . The extremely low VE in Figure 1 The decrease in VE associated with the RBD substitution is biologically reasonable according to the latest 115 findings in literature. Evidence suggests that the neutralization potency of antibodies is reduced in the 116 vaccine-elicited sera against SARS-CoV-2 variants encoding K417N/E484K/N501Y [6, 9] . Another mutation, 117 N439K, was shown to modestly enhance the binding affinity to the host receptor hACE2 and confer resistance 118 against several neutralizing monoclonal antibodies [10] . Moreover, the 475V and 477N variants were also 119 reported to reduce antibody-mediated immunity [11, 12] . From the perspective of genetic epidemiology, our 120 findings highlighted that RBD mutations may weaken vaccine protection. As for non-RBD substitutions, 121 further investigation is needed to determine their roles in viral immune escape. 122 In summary, this study identified a negative relationship between VE and genetic mismatch of circulating 123 SARS-CoV-2 strains against vaccine strains in three genomic regions. This study has several limitations. 124 Although the current model reached good statistical significance, the complexity of the model is restricted by 125 the sample size of the available studies reporting VE. Thus, the platform effect and population effect on 126 vaccine performance cannot be addressed. Secondly, the existing genetic mismatch was evaluated by 127 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.22.21254079 doi: medRxiv preprint measuring genetic distance, and other chemical and spatial structure changes associated with amino acid 128 substitutions were not considered. Nevertheless, we demonstrated that genetic mismatch explains a sizable 129 portion of VE deviations in clinical trials. These results imply that it is essential to monitor newly arising 130 variants, and COVID-19 vaccines will need to be updated periodically to avoid potential loss of efficacy. 131 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The ethical approval or individual consent was not applicable. 148 149 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. COVID-19 VACCINE TRACKER Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine 155 against the B.1.351 Variant In silico prediction of influenza vaccine effectiveness by sequence 157 analysis SARS-CoV-2 501Y.V2 escapes neutralization by South 159 African COVID-19 donor plasma SARS-CoV-2 B. 1.1. 7 escape from mRNA vaccine-161 elicited neutralizing antibodies The first 12 months of COVID-19: a timeline of immunological 163 insights Global initiative on sharing all influenza data -from vision to reality mRNA vaccine-elicited antibodies to SARS-CoV-2 and 167 circulating variants Circulating SARS-CoV-2 spike N439K variants 169 maintain fitness while evading antibody-mediated immunity Identification of SARS-CoV-2 spike mutations that 171 attenuate monoclonal and serum antibody neutralization The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and 173 Antigenicity No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.